Participated · Equity · May 2026

VirtualBrowser develops a Remote Browser Isolation solution that prevents direct contact between user endpoints and the web by executing browsing on isolated servers and returning only a visual pixel stream. The platform is used by more than 150,000 users across over 100 organizations, including Thales, Dassault Aviation, Naval Group, Bouygues Telecom, the EU Council, CNIL and the French foreign ministry. It is the only web navigation security solution certified “CSPN” by ANSSI according to the article. The company is positioning its technology not only for secure browsing but also as an alternative to VPNs and VDI for partner and third‑party access, offering granular controls like download disablement, print blocking and dynamic watermarks. VirtualBrowser is developing a mobile app (beta on Android and iOS, validated by Apple to be a default browser) to address smishing and aims to expand further across Europe and via MSSP/integration partners. The recent €6 million raise will fund product development and accelerate European and channel expansion.

Participated · Series A · Jul 2023

Founded in 2016, Exeliom Biosciences engineers live-bacterial, NOD2-targeting immunomodulators to boost patients’ innate immune responses. Its lead candidate, EXL01, is a Faecalibacterium prausnitzii-derived therapy that reprograms macrophages and the tumour micro-environment to overcome resistance to existing treatments. EXL01 is currently being tested in three Phase 2 oncology trials alongside immune-checkpoint inhibitors, including what the company calls the largest randomised Phase 2 study worldwide of a bacterial therapy in gastric cancer. The programme also includes a Phase 2 trial in Crohn’s disease and a study aimed at preventing recurrent Clostridioides difficile infection. Fresh capital will fund proof-of-concept Phase 2 work, preparation for a new U.S. cancer indication and broader international expansion. To date, Exeliom has secured nearly €30 million in combined dilutive and non-dilutive financing, underscoring strong investor confidence in its precision immunotherapy platform.

Led · Equity · May 2022

Vade builds AI-powered threat detection and response technology focused on email security, with a flagship product called Vade for M365 that is purpose-built for MSPs. The company protects more than 1 billion corporate and consumer mailboxes and serves ISPs, MSPs, and SMBs. Its solutions defend against malware/ransomware, spear phishing/business email compromise, and phishing. Led by CEO Georges Lotigier and founded in 2009, Vade has almost 200 employees and plans to add about 80 more by the end of the calendar year. The company intends to use new funding to accelerate international expansion and enhance its cybersecurity products for ISPs, MSPs, and SMBs. Vade also plans increased emphasis on developing MSSP-tailored solutions with improved installation and high efficiency.

Participated · Series B · Jan 2018

Pherecydes Pharma is a biotechnology company that develops precision phage therapy to treat resistant and/or complicated bacterial infections. The company has developed a portfolio of phages targeting Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, which together account for more than two thirds of hospital-acquired resistant infections. Its precision phage therapy approach has been applied in 26 patients in the context of compassionate use under the supervision of the French National Agency for the Safety of Medicines (ANSM). Pherecydes launched clinical trials for anti‑Staphylococcus aureus phages in 2021 and planned the implementation of Early Access Programs during the second half of the year. Headquartered in Nantes and founded in 2006, the company has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research. Financially, Pherecydes strengthened its cash position by securing a €2 million non‑dilutive, interest‑bearing loan from Bpifrance. Pherecydes Pharma is a biotechnology company developing therapeutic bacteriophages to treat bacterial infections, particularly hospital-acquired and antibiotic-resistant cases. Its core programs include PHOSA for severe Staphylococcus aureus infections and PNEUMOPHAGE for Pseudomonas aeruginosa respiratory infections. The company plans to use new funding to produce phages for compassionate use (ATU) under GMP and to advance PHOSA and PNEUMOPHAGE into clinical phases in 2018 and 2019. It will also build a 10,000 sq ft (≈1,000 m2) pharmaceutical production unit in Nantes and launch additional research programs in 2018–2019. Financially, Pherecydes raised €8.7M in this Series B and has cumulatively raised €13.6M to date; it also receives public grants for projects such as PneumoPhage, Phosa and Phagoburn. The company is led by CEO Guy-Charles Fanneau de La Horie and COO Jérôme Gabard and employs twelve people.

Participated · Equity · Oct 2017

aveni develops and supplies wet deposition technologies and Electrografting™ chemistries and processes aimed at 2D interconnects and 3D TSV packaging for the semiconductor and electronics industry. The company is led by CEO Bruno Morel and is based in Massy, France. It completed a €8.9M ($10.5M) Series B financing. Backers named in the round include Merck Ventures and existing investors such as Samsung Venture Investment Corporation, Panasonic, ALIAD (Air Liquide Venture Capital), Auriga Partners, Supernova and Idinvest Partners. aveni intends to use the funds to commercialize its technologies. No operating metrics were disclosed in the article. aveni (fka Alchimer S.A.) develops wet electrochemical metallization processes—Electrografting (eG™) for conductive substrates and Chemicalgrafting (cG™) for nonconductive substrates—targeted at damascene, TSVs, MEMS and other electronic applications. The company’s technology enables growth of high‑quality thin films and is currently in the qualification phase for the dual‑damascene process at the 10nm node with three leading logic manufacturers. aveni secured $13.5M in funding to support commercial expansion and technology adoption. It announced formation of a U.S. subsidiary based in Silicon Valley to support the U.S. market. Led by CEO Bruno Morel, the company plans to use the proceeds to grow and expand adoption of its metallization products.